NRG Therapeutics shortlisted in this year’s Genesis 2022 BioNewsRound Award

  • Published on 5th December 2022 by Stevenage Bioscience Catalyst
Share
  • Vote for SBC-based company shortlisted for BioNewsRound award
  • Voting closes at 14:00 GMT on Wednesday 7 th December 2022

Following announcement of its successful £16m financing, NRG Therapeutics (NRG) has been short listed by One Nucleus for the Genesis 2022 BioNewsRound Award. NRG is focused on advancing mitochondrial therapeutics for Parkinson’s and ALS. With a powerful mix of innovation, tenacity, and hope, the team is employing pioneering science with the goal of delivering first-in-class disease-modifying therapies.

With this £16m series A financing, NRG has moved from a virtual office in Cambridge to its base at the Stevenage Bioscience Catalyst (SBC) which provides laboratory space and access to other services as it grows. 

CEO of NRG Therapeutics, Dr Neil Miller explained: “SBC is ideally located between Cambridge and London and within easy reach of the academic centres of the golden triangle. It offers easy access by train and is also close to the R & D site of a major pharma, GSK, so provides a pool of like-minded scientists for networking and recruitment as we grow.”

Dr Sally Ann Forsyth OBE, CEO of Stevenage Bioscience Catalyst, said: “We are thrilled to have welcomed Neil and the team at NRG Therapeutics to SBC, following their successful financing. It's good to see an SBC-based organisation shortlisted for the Genesis 2022 BioNewsRound award. Please join us in voting for Neil and the NRG team.”

Voting closes at 14:00 GMT on Wednesday 7 th December 2022.

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.